Categories AlphaGraphs, Earnings, Other Industries

Bausch Health stock rises on guidance hike

Bausch Health Companies Inc. (NYSE: BHC) said its revenues for the second quarter edged up 1% to $2.15 billion, in line with the average analysts’ estimate. Revenues at its biggest Bausch + Lomb/International segment was flat year-over-year.  

GAAP net loss narrowed to 49 cents per share, compared to $2.49 per share in the same period last year, driven by lower interest expense and lower loss on extinguishment of debt. On an adjusted basis, net income missed street view by a cent.

Bausch Health Companies Inc. (NYSE: BHC) said its revenues for the second quarter edged up 1% to $2.15 billion, in line with the average analysts’ estimate.

BHC stock gained 2.9% following the earnings announcement. BHC shares have been trading sidewise in the trailing 12 months, and is currently up 3%.

The Canadian pharma giant also raised its revenue and its adjusted EBITDA guidance range for the full-year. It currently expects full-year revenues of $8.40 billion – $8.60 billion, compared to the earlier estimate of $8.35 billion – $8.55 billion.

READ: CVS Health has the right prescription for growth in Q2

Outlook on adjusted EBITDA was raised to $3.425 billion – $3.575 billion, from the prior estimate of $3.40 billion – $3.55 billion.

CEO Joseph C. Papa said, “Looking to the second half of 2019, we expect a number of catalysts to drive growth across our core business segments as we continue to reduce debt, increase R&D and further grow our newly launched products.”   

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top